ArticleNature microbiology2024
Most azole resistance mutations in the Candida albicans drug target confer cross-resistance without intrinsic fitness cost.
Camille Bédard et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
27 papers cite it
this papercites it